Skip to main content
. Author manuscript; available in PMC: 2015 Aug 15.
Published in final edited form as: J Immunol. 2014 Jul 7;193(4):1709–1716. doi: 10.4049/jimmunol.1400034

Fig 4. Prolonged tumor survival after treatment with IL2 and anti-TGFβ is NK and CD8 T cell-dependent.

Fig 4

(A–B) Percent survival of mice treated with either rIgG, LD IL2, 1D11, or CT with or without NK and/or CD8 T cell depletion. Data are representative of two independent experiments with 8 mice per group. Statistical analysis was performed using logrank test. Significance for IL2 single therapy versus CT therapy treated mice (A) and between CT therapy and CT plus anti-NK1.1/CD8 treated mice (B) is shown (***p<0.001)